Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.750
Neutral
RSI(14)
59.682
Neutral
STOCH(KDJ)(9,3,3)
23.998
Neutral
ATR(14)
1.602
Low Volatility
CCI(14)
-93.637
Neutral
Williams %R
73.070
Sell
TRIX(12,20)
0.547
Sell
StochRSI(14)
51.631
Buy
LivaNova PLC
LIVN62.820USD
+0.740+1.19%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
3.43BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of LivaNova PLC
Currency: USD Updated: 2025-12-19Key Insights
LivaNova PLC's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 2/208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 67.73.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
LivaNova PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
10
analysts
Buy
Current Rating
67.732
Target Price
+8.08%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
LivaNova PLC Highlights
StrengthsRisks
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 22.67% year-on-year.
Fairly Valued
The company’s latest PE is -15.77, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 56.86M shares, decreasing 13.00% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 12.03K shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-19The current financial score of LivaNova PLC is 9.06, ranking 15/208 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 357.75M, representing a year-over-year increase of 12.46%, while its net profit experienced a year-over-year increase of 18.72%.
Score
Financials
9.04
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
10.00
Operational Efficiency
9.58
Growth Potential
9.18
Shareholder Returns
7.49
LivaNova PLC's Company Valuation
Currency: USD Updated: 2025-12-19The current valuation score of LivaNova PLC is 7.03, ranking 135/208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -15.77, which is -6468.96% below the recent high of 1004.49 and -1031.46% above the recent low of -178.45.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 2/208
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-19The current earnings forecast score of LivaNova PLC is 8.20, ranking 54/208 in the Healthcare Equipment & Supplies industry. The average price target for LivaNova PLC is 67.50, with a high of 86.00 and a low of 53.32.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
10
analysts
Buy
Current Rating
67.732
Target Price
+8.08%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
112
Total
6
Median
9
Average
Company name
Ratings
Analysts
LivaNova PLC
LIVN
10
Medtronic PLC
MDT
35
Stryker Corp
SYK
32
Abbott Laboratories
ABT
31
Dexcom Inc
DXCM
31
Zimmer Biomet Holdings Inc
ZBH
30
1
2
3
...
23
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-19The current price momentum score of LivaNova PLC is 9.24, ranking 19/208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 67.77 and the support level at 55.68, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
62.824
Sell
MA10
62.956
Sell
MA20
62.681
Buy
MA50
57.057
Buy
MA100
55.083
Buy
MA200
48.354
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-19The current institutional shareholding score of LivaNova PLC is 10.00, ranking 1/208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 104.13%, representing a quarter-over-quarter increase of 0.01%. The largest institutional shareholder is PRIMECAP Management, holding a total of 4.44M shares, representing 8.14% of shares outstanding, with 3.69% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
Millennium Management LLC
Artisan Partners Limited Partnership
Wellington Management Company, LLP
State Street Investment Management (US)
Dimensional Fund Advisors, L.P.
AQR Capital Management, LLC
Geode Capital Management, L.L.C.
1
2
Risk Assessment
Currency: USD Updated: 2025-12-19The current risk assessment score of LivaNova PLC is 7.86, ranking 28/208 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.97. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.97
VaR
+3.18%
240-Day Maximum Drawdown
+33.27%
240-Day Volatility
+39.88%
Return
Best Daily Return
60 days
+9.35%
120 days
+11.15%
5 years
+23.72%
Worst Daily Return
60 days
-5.80%
120 days
-5.80%
5 years
-15.76%
Sharpe Ratio
60 days
+1.95
120 days
+1.99
5 years
+0.08
Risk Assessment
Maximum Drawdown
240 days
+33.27%
3 years
+47.23%
5 years
+63.48%
Return-to-Drawdown Ratio
240 days
+0.97
3 years
+0.09
5 years
-0.06
Skewness
240 days
+1.93
3 years
+1.42
5 years
+0.88
Volatility
Realised Volatility
240 days
+39.88%
5 years
+40.03%
Standardised True Range
240 days
+2.45%
5 years
+3.17%
Downside Risk-Adjusted Return
120 days
+407.56%
240 days
+407.56%
Maximum Daily Upside Volatility
60 days
+33.39%
Maximum Daily Downside Volatility
60 days
+26.22%
Liquidity
Average Turnover Rate
60 days
+1.21%
120 days
+1.35%
5 years
--
Turnover Deviation
20 days
+20.00%
60 days
+4.03%
120 days
+15.65%
Peer Comparison
Healthcare Equipment & Supplies
LivaNova PLC
LIVN
8.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Edwards Lifesciences Corp
EW
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Artivion Inc
AORT
8.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
LNTH
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Tactile Systems Technology Inc
TCMD
8.43 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AXGN
8.40 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of LivaNova PLC?
The TradingKey Stock Score provides a comprehensive assessment of LivaNova PLC based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of LivaNova PLC’s performance and outlook.
How do we generate the financial health score of LivaNova PLC?
To generate the financial health score of LivaNova PLC, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects LivaNova PLC's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of LivaNova PLC.
How do we generate the company valuation score of LivaNova PLC?
To generate the company valuation score of LivaNova PLC, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare LivaNova PLC’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of LivaNova PLC’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of LivaNova PLC.
How do we generate the earnings forecast score of LivaNova PLC?
To calculate the earnings forecast score of LivaNova PLC, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on LivaNova PLC’s future.
How do we generate the price momentum score of LivaNova PLC?
When generating the price momentum score for LivaNova PLC, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of LivaNova PLC’s prices. A higher score indicates a more stable short-term price trend for LivaNova PLC.
How do we generate the institutional confidence score of LivaNova PLC?
To generate the institutional confidence score of LivaNova PLC, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about LivaNova PLC’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of LivaNova PLC.
How do we generate the risk management score of LivaNova PLC?
To assess the risk management score of LivaNova PLC, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of LivaNova PLC’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of LivaNova PLC.
